Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW003 in Chinese Adolescents With Obesity
NCT07143227Phase 1Completed
- Sponsor
- Sciwind Biosciences
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ecnoglutide in obesity (4 arms), sponsored by Sciwind Biosciences. Primary endpoint: Number and severity of adverse events at 20 weeks. Started Aug 2025; status: completed.
02
Drugs
ecnoglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07143227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143227.